ChromaDex Corporation (CDXC)

Market Cap	413.37M
Revenue (ttm)	91.67M
Net Income (ttm)	1.49M
Shares Out	76.55M
EPS (ttm)	0.02
PE Ratio	274.45
Forward PE	51.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,432
Open	5.46
Previous Close	5.49
Day's Range	5.35 - 5.51
52-Week Range	1.36 - 7.97
Beta	2.15
Analysts	Strong Buy
Price Target	8.00 (+48.15%)
Earnings Date	Oct 31, 2024

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufactur...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 1999
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXC
• Website: https://www.chromadex.com

Financial Performance

In 2023, ChromaDex's revenue was $83.57 million, an increase of 15.99% compared to the previous year's $72.05 million. Losses were -$4.94 million, -70.15% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CDXC stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 48.15% from the latest price.

Price Target

$8.0

(48.15% upside)

Analyst Consensus: Strong Buy